Oncology, Screening & Prevention, Women's Health
Better outcomes for patients with HR+/HER2- breast cancer: spotlight on CDK4/6 inhibitors
This 1-hour interactive online education program is designed to provide medical oncologists with a practical overview of CDK4/6 inhibitors, and their current use in the Australian breast cancer management landscape. The program highlights real-world evidence pertaining to CDK4/6 inhibitors, and features video Q&A with Dr Shom Goel of the Peter MacCallum Cancer Centre to highlight practical applications of established and emerging data.
This program has been endorsed by the Clinical Oncology Society of Australia (COSA), and sponsored by an independent educational grant provided by Pfizer.
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
1
ACCREDITATION
RACP
EXPIRY DATE
2023-06-08
This 1-hour interactive online education program is designed to provide medical oncologists with a practical overview of CDK4/6 inhibitors, and their current use in the Australian breast cancer management landscape. The program highlights real-world evidence pertaining to CDK4/6 inhibitors, and features video Q&A with Dr Shom Goel of the Peter MacCallum Cancer Centre to highlight practical applications of established and emerging data.
This program has been endorsed by the Clinical Oncology Society of Australia (COSA), and sponsored by an independent educational grant provided by Pfizer.
Faculty
Dr Shom Goel, B Med Sci (Hons), MBBS (Hons), FRACP, PhD
(Melbourne, VIC)
Dr Elgene Lim, MBBS FRACP PhD
(Sydney, NSW)
Dr Otto Metzger, M.D.
(Boston, MA)
Learning objectives
On completion of this program, participants will be better able to:
- Outline efficacy data for CDK4/6 inhibitors as first- and second-line therapy for advanced hormone receptor-positive breast cancer
- Identify when is it appropriate to use a CDK4/6 inhibitor as first-line therapy for advanced hormone receptor-positive breast cancer
- Describe the adverse effects of the available CDK4/6 inhibitors, how they differ and what the guidelines recommend regarding monitoring and management of toxicity
- Recognise baseline risk of adverse effects and potential drug-drug interactions